Bacillus subtilis lipase mutant as well as preparation method and application thereof

Through the transformation and genetic engineering technology of Bacillus subtilis lipase gene, a lipase mutant with improved catalytic activity and thermal stability was constructed, which solved the problem of insufficient activity of Bacillus subtilis lipase in industrial applications, and achieved the goal of Effective catalysis and wide application at high temperatures.

CN118931876APending Publication Date: 2024-11-12JIANGSU UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411056903.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Bacillus subtilis lipase has poor catalytic activity and insufficient thermal stability in industrial applications, which affects its application effect in food processing, oil processing and other fields.

Method used

By modifying the Bacillus subtilis lipase gene, the isoleucine at a specific location is changed to valine, the Bacillus subtilis lipase mutant is constructed, and expressed and purified in E. coli through genetic engineering to obtain improved catalysis Active and thermally stable lipase mutants.

Benefits of technology

The catalytic activity and thermal stability of lipase are significantly improved. The enzyme activity of the mutant remains above 90% at 65°C. It is suitable for improving the digestibility of animal feed oil and fat, and is suitable for large-scale industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931876A_ABST
    Figure CN118931876A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of bioengineering, and particularly relates to a bacillus subtilis lipase mutant as well as a preparation method and application thereof. The amino acid sequence of the lipase mutant is as shown in SEQ ID NO.2, the lipase mutant is obtained by mutating wild lipase with the amino acid sequence as shown in SEQ ID NO.1, the mutation mode is that 157-site isoleucine is changed into valine, and the coding gene of the lipase mutant is as shown in SEQ ID NO.3. The invention provides novel lipase with high enzymatic activity, the mutant has ideal catalytic characteristic and high temperature tolerance, and the enzymatic activity of the mutant I157V is improved by 3.75 times compared with that of a wild type; the lipase high-activity mutant can more easily catalyze triglyceride to be decomposed into glycerol and fatty acid which are easier to digest, is suitable for improving the grease digestibility of animal feed, is suitable for industrial large-scale low-cost production, and has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of bioengineering, and in particular relates to a Bacillus subtilis lipase mutant and a preparation method and application thereof. Background Art

[0002] Lipase, also known as triglyceride hydrolase, mainly catalyzes the hydrolysis of fatty esters, gradually hydrolyzing triglycerides into fatty acids, diglycerides, monoglycerides and glycerol; it can also catalyze the synthesis and conversion of esters, such as acidolysis, alcoholysis, aminolysis, esterification and ester synthesis. Moreover, lipase can also catalyze esterification, transesterification and transesterification reactions in non-aqueous phases with high selectivity and specificity; it has been widely used in industries and biotechnology such as bioenergy, oil processing, food processing, leather processing and feed additives.

[0003] Lipases are widely distributed in the natural environment and can be obtained from animals, plants and microorganisms. Among them, microbial lipases occupy a key position in industrial applications; for example, Bacillus subtilis lipase has important applications in industrial processes such as food processing, oil processing, and leather processing. It can catalyze the hydrolysis of fats and is used to produce fatty acids, diglycerides and other compounds in food. By hydrolyzing oils and fats with lipase, the utilization rate of oils and fats can be improved, environmental pollution can be reduced, and the nutritional characteristics and digestibility of the products can be improved. However, in industrial applications, the catalytic activity of Bacillus subtilis lipase is still affected by factors such as temperature, organic solvents in the reaction medium, and substrate concentration, which greatly reduces its application effect.

[0004] Therefore, how to improve the catalytic activity or thermal stability of Bacillus subtilis lipase so that Bacillus subtilis lipase can be more widely used in industry is a technical problem that urgently needs to be solved. Summary of the invention

[0005] In view of the shortcomings of the prior art, the present invention transforms the Bacillus subtilis lipase gene to make it a lipase with improved catalytic activity. The prepared Bacillus subtilis lipase mutant has excellent activity, solving the problem that the catalytic activity of Bacillus subtilis lipase is poor and unsatisfactory in industrial production.

[0006] The technical solution of the present invention is as follows:

[0007] A Bacillus subtilis lipase mutant is obtained by replacing the amino acid sequence of the Bacillus subtilis lipase. The amino acid sequence of the Bacillus subtilis lipase is shown in SEQ ID NO.1.

[0008] Specifically, the Bacillus subtilis lipase mutant is obtained by changing the 157th isoleucine in the Bacillus subtilis lipase amino acid sequence SEQ ID NO.1 to valine.

[0009] The amino acid sequence of the Bacillus subtilis lipase mutant of the present invention is shown in SEQ ID NO.2.

[0010] The nucleotide sequence of the gene encoding the Bacillus subtilis lipase mutant is shown in SEQ ID NO.3.

[0011] A recombinant expression vector, characterized in that it contains the gene described in SEQ ID NO.3.

[0012] A genetically engineered bacterium, wherein the preparation method of the recombinant genetically engineered bacterium is as follows: the gene described in SEQ ID NO.3 is cloned into the expression vector pTXB1, and the competent cells of Escherichia coli are transformed to obtain the recombinant genetically engineered bacterium.

[0013] In another aspect of the present invention, nucleotide sequences encoding the same protein as the coding gene SEQ ID NO.3 but different from the nucleotide sequence shown in SEQ ID NO.3 or its complementary sequence due to the degeneracy of the genetic code are also within the protection scope of the present invention.

[0014] In another aspect of the present invention, the present invention also includes a plasmid carrying a lipase mutant encoding a gene sequence of SEQ ID NO.3.

[0015] The present invention also provides a method for constructing a Bacillus subtilis lipase mutant, comprising the following steps:

[0016] (1) Using the recombinant plasmid containing the Bacillus subtilis lipase gene connected to the vector as a template, primers were designed to perform site-directed mutagenesis PCR amplification to obtain a mutant product;

[0017] (2) Then add 1 μL of DnpⅠ digestion enzyme to 10 μL of mutant product, mix well, and incubate in a PCR instrument at 37°C for 60 min to obtain the digestion product;

[0018] (3) Add 10 μL of digestion product to 100 μL of DH5α competent cells, cool in an ice bath, heat shock, and then cool again, add 500 μL-700 μL of LB medium, culture at 37°C, 180 rpm for 2 h, centrifuge and retain part of the clear liquid to suspend the precipitate, take all the bacterial liquid to plate, and culture in a constant temperature incubator at 37°C for 16 h;

[0019] (4) Screening and verification of positive clones: single colonies were selected and placed in LB medium. After culturing at 37°C and 180 rpm for 5-6 h, PCR identification was performed. The screened positive clones were sent for sequencing, and the sequencing results were compared with the original sequences.

[0020] (5) Find the recombinant plasmid with the correct mutation; transfer the mutant plasmid into BL21 (DE3) competent cells for expression; and then ferment and purify to obtain the Bacillus subtilis lipase mutant.

[0021] In the above step (1), the site-directed mutagenesis primer is:

[0022] F: TTCATGGTGTTGGTCATGTTGGTCTGCTGTATAG;

[0023] R: TATACAGCAGACCAACATGACCAACACCATGAATC.

[0024] The present invention also provides the use of the Bacillus subtilis lipase mutant in hydrolyzing fats and oils in animal feed.

[0025] The present invention additionally provides a feed additive product, which comprises the Bacillus subtilis lipase mutant.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] The present invention provides a Bacillus subtilis lipase mutant, wherein the mutated gene and pTXB1 are used to construct a recombinant plasmid, which is transformed into a corresponding host bacterium, and antibiotics such as ampicillin are added to a plate to screen and obtain a genetically engineered bacterium of the lipase mutant, and then a new lipase mutant is obtained by fermentation and purification. The prepared Bacillus subtilis lipase mutant has excellent vitality and significantly improved catalytic activity, thereby solving the problem that the catalytic activity of Bacillus subtilis lipase is poor and unsatisfactory in industrial production.

[0028] The mutant of the lipase prepared by the present invention and the wild-type lipase are tolerant to high temperatures. Experiments have shown that the enzyme activity after mutation is significantly higher than the enzyme activity before mutation at any temperature and time. When the temperature reaches 65°C, the enzyme activity of the wild-type lipase is less than 70%, while the enzyme activity of the mutant of the present invention is still maintained at more than 90%. The comparison effect is very obvious, which significantly improves its temperature tolerance. Moreover, the lipase mutant prepared by the present invention can effectively hydrolyze the oil in animal feed, and is more likely to catalyze the decomposition of triglycerides into more easily digestible glycerol and fatty acids. It is suitable for improving the oil digestibility of animal feed, and is suitable for industrial large-scale low-cost production. It has potential application value in the hydrolysis of oil in animal feed processing, and has broad market application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is the SDS-PAGE analysis of the wild-type and mutant lipase expressed in Example 2, wherein M: low molecular weight protein marker; A and B represent the purified wild-type enzyme and mutant, respectively;

[0030] Figure 2 Determination of the optimal reaction pH of the wild type and mutant lipase in Example 4;

[0031] Figure 3 Determination of the optimum reaction temperature of the wild type and mutant lipase in Example 5;

[0032] Figure 4 This is the hydrolysis test of fats in animal feed by the wild type and mutant lipase in Example 6. DETAILED DESCRIPTION

[0033] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0034] It should be understood that the terms described in the present invention are only for describing specific embodiments and are not intended to limit the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as commonly understood by those skilled in the art in the art to which the present invention relates.

[0035] Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials related to the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0036] As used herein, "include", "comprising", "having", "containing", etc. are all open terms, which means including but not limited to. In addition, it should be understood that the terms described in the present invention are only for describing specific embodiments and are not used to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper limit and the lower limit of the range is also specifically disclosed. Each smaller range between any stated value or intermediate value in the stated range and any other stated value or intermediate value in the range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the range.

[0037] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0038] "Wild type" refers to the form of a material or substance that is the same as that found in nature. For example, a wild-type protein or nucleic acid sequence is the original sequence form that can be isolated from nature and has not been artificially modified and exists in an organism.

[0039] The protein spatial structure of Bacillus subtilis lipase was simulated and analyzed, and its mutation site was determined to be the mutation of isoleucine at position 157 to valine. Specific implementation scheme Using the Bacillus subtilis lipase gene as a template, the Bacillus subtilis lipase gene was mutated by a site-directed mutagenesis method to obtain a new lipase gene, and the mutant gene was connected to a pTXB1 vector to construct a recombinant plasmid, which was transferred into a corresponding host bacterium for heterologous expression, and the lipase mutant was obtained by fermentation. The mutant has a relatively ideal catalytic activity and is therefore suitable for industrial production.

[0040] Unless otherwise specified, the reagents and materials used in the present invention are conventional commercially available products.

[0041] Gene source strain: Bacillus subtilis;

[0042] Expression host bacteria and vector: BL21 (DE3) strain and pTXB1 vector;

[0043] Cloning host bacteria: E. coli DH5α competent cells were purchased from Sangon Biotech (Shanghai) Co., Ltd.;

[0044] BL21(DE3) electroporation competent cells were purchased from Beijing Biomed Gene Technology Co., Ltd.;

[0045] The mutation primers were synthesized by Sangon Biotechnology (Shanghai) Co., Ltd.

[0046] Main reagents: DNA Marker, protein Marker (TaKaRa); Plasmid Mini Kit I (Omega Trading Co., Ltd.); Gel Extraction Kit (Omega Trading Co., Ltd.); p-nitrophenol palmitate (p-NPP) (Sigma); KOD Plus Neo high-fidelity PCR enzyme (Toyobo Biotechnology Co., Ltd.); TGEX buffer composed of pH 7.5, 20mM Tris-HCl, 10% Glycerol, 0.7M NaCl, 1mM EDTA, and 0.1% TritonX-100.

[0047] Experimental instruments: centrifuge (Eppendorf); PCR amplifier (Hangzhou Bioray Technology Co., Ltd.); MK-20 metal bath (Hangzhou Aosheng Company); nucleic acid electrophoresis instrument (Beijing Liuyi Biotechnology Co., Ltd.); protein electrophoresis instrument (Amersham Bioscience); gel imager (Bio-Rad); SpectraMax Plus 384 microplate reader (Molecular Devices, USA); digital display constant temperature water bath (Shanghai Boxun Medical Biological Instrument Co., Ltd.).

[0048] Main culture medium: LB medium: 0.5% (w / v) yeast extract, 1.0% (w / v) tryptone, 1.0% (w / v) sodium chloride, dissolved in double distilled water.

[0049] Embodiment 1:

[0050] Preparation of Bacillus subtilis lipase mutants

[0051] The method for constructing the expression vector of the Bacillus subtilis lipase mutant of the embodiment of the present invention comprises the following steps:

[0052] (1) Site-directed mutagenesis:

[0053] The expression plasmid pTXB1-BSLA of Bacillus subtilis lipase BSLA was constructed, that is, the gene of Bacillus subtilis lipase (Genbank ID: NC_000964.3) was inserted into the vector pTXB1 to construct a recombinant plasmid. Using the constructed recombinant plasmid pTXB1-BSLA as a template, site-directed mutagenesis primers were designed, 20 μL mutation system was prepared, and KOD Plus Neo high-fidelity PCR enzyme was used for mutation PCR amplification to obtain the mutation product;

[0054] The site-directed mutagenesis primers are as follows:

[0055] F: TTCATGGTGTTGGTCATGTTGGTCTGCTGTATAG;

[0056] R: TATACAGCAGACCAACATGACCAACACCATGAATC.

[0057] (2) Mutation PCR verification:

[0058] Take 10 μL of the mutant product and perform 1% agarose gel electrophoresis detection; after the band is correct, add 1 μL of DnpⅠ digestion enzyme to the mutant product, flick to mix, and incubate at 37℃ for 60 minutes in a PCR instrument to obtain the digestion product;

[0059] (3) Conversion:

[0060] Add 10 μL of digestion product to 100 μL of E. coli DH5α competent cells, flick to mix, and place on ice for 30 min; heat shock at 42°C for 45 s and immediately place on ice for 10 min; add 500 μL of LB medium, culture at 180 rpm and 37°C for 1 h; centrifuge at 7000 rpm for 3 min, discard the supernatant, retain 100-150 μL of supernatant and flick to suspend the bacteria, take all the bacterial solution to spread on the plate, culture at 37°C overnight (16 h), and grow colonies on the plate surface;

[0061] (4) Positive clone verification:

[0062] A single colony was picked and placed in 500 μL of LB medium with corresponding resistance, cultured at 200 rpm for 5-6 hours, and then identified by PCR; the screened positive clones were sent for sequencing, and the sequencing results were compared with the original sequence.

[0063] The Bacillus subtilis lipase gene mutation was carried out according to the above experimental method and then sent to Jinweizhi Biotechnology Co., Ltd. for sequencing. The amino acid sequence was such as SEQ ID NO.2, and the corresponding lipase nucleotide sequence was such as sequence SEQ ID NO.3. The transformed strain had lipase activity. The strain was cultured for induced expression to obtain the protein expression product for enzymatic property determination.

[0064] Embodiment 2:

[0065] Construction, expression and purification of Bacillus subtilis lipase mutant expression strain;

[0066] (1) After the positive transformants with correct sequencing were amplified and cultured overnight in LB liquid medium, the plasmid was extracted and a total of 10 μg of the linearized plasmid product was mixed with BL21 (DE3) competent cells for electroporation transformation;

[0067] (2) Immediately after electroporation, 1 mL of RM medium was added, incubated at 37°C for 2 h, and then evenly spread on a plate with ampicillin (ampicillin concentration was 100 μg / mL) for screening; after culturing for 16 h, positive transformants were selected to obtain single colonies of the engineered strain;

[0068] (3) Inoculate a single colony of the engineered strain into 50 mL of LB medium, culture at 37°C and 220 rpm until the OD value is 0.6-0.8, inoculate 5% of the inoculum into 400 mL of LB medium, culture at 37°C and 220 rpm for 3 h, induce with 1% isopropylthiogalactoside (IPTG), and ferment at 18°C ​​and 220 rpm for 16 h;

[0069] (4) The fermentation broth was centrifuged at 4°C and 8000 r / min for 15 min, cleaned and centrifuged twice with sodium hydrogen phosphate buffer, the cell precipitate was collected, and the cell precipitate was broken by ultrasonic disruptor. After centrifugation at 4°C and 8000 r / min for 15 min, the supernatant was collected. The supernatant was filtered with a 0.45 μm filter membrane and purified with a chitin resin chromatography column. The chromatography column was first equilibrated with a TGEX buffer (pH 8.0), and eluted overnight with a TGEX solution containing 50 mM DTT to obtain a Bacillus subtilis lipase mutant, which was recorded as mutant I157V. The wild-type lipase was recorded as WT, and the amino acid sequence was shown in SEQ ID NO.1.

[0070] Figure 1 SDS-PAGE analysis of the expressed wild-type lipase and mutants, where M is a low molecular weight protein marker; A and B represent the purified wild-type enzyme and mutant, respectively; the results show that Figure 1 As shown, the protein purity is above 95%.

[0071] Embodiment 3:

[0072] Determination of lipase mutant enzymatic activity;

[0073] The enzyme activity unit is defined as: under certain conditions, the amount of enzyme required to hydrolyze the substrate p-nitrophenyl palmitate (p-NPP) per minute to produce 1 μmoL of p-nitrophenyl acid (p-NP) is one enzyme activity, and the unit is expressed in U.

[0074] p-Nitrophenol method: Pipette 420 μL of phosphate buffer with a pH of 8.0 into a centrifuge tube, add 30 μL of 10 mM substrate p-nitrophenyl palmitate (p-NPP), mix thoroughly and preheat at 37°C for 2 min, then add 50 μL of diluted enzyme solution, react for 5 min, add 50 μL of 10% SDS to terminate the reaction, and finally add 500 μL of 0.5 M sodium carbonate for color development, and measure the OD value at a wavelength of 405 nm using an enzyme reader.

[0075] Table 1: Enzyme activity assay results

[0076]

[0077] The results of mutant enzyme activity assay are shown in the table: the enzyme activity of mutant I157V was 3.75 times higher than that of WT.

[0078] Embodiment 4:

[0079] Determination of optimal pH for lipase;

[0080] The enzymatic activity of lipase was determined in buffer systems with different pH values ​​(2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, and 12.0). The enzyme solution was diluted to an appropriate multiple, and the optimal pH of the lipase mutant was determined at 37°C using the p-nitrophenol method.

[0081] The optimum pH value of lipase enzymatic reaction is as follows Figure 2 As shown, the optimum pH of mutant I157V and wild-type (WT) lipase is 8, with no significant change.

[0082] Embodiment 5:

[0083] Determination of optimal temperature of lipase;

[0084] According to the lipase activity assay method, under the above-mentioned optimal pH conditions, the reaction system was placed at different temperatures (30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C) for reaction.

[0085] Figure 3 To determine the optimal reaction temperature of wild-type and mutant lipase;

[0086] The results are as follows Figure 3 As shown, the optimum temperature of Bacillus subtilis lipase WT is 50°C, and the optimum temperature of mutant I157V is 55°C.

[0087] However, as the temperature rises, when the temperature reaches 65°C, the enzyme activity of the wild-type (WT) lipase is less than 70%, while the enzyme activity of the mutant I157V of the present invention is still maintained at more than 90%, and the comparison effect is very significant.

[0088] Embodiment 6:

[0089] The hydrolysis effect of lipase mutants on fats and oils in animal feed;

[0090] (1) The reaction mixture consisted of 250 uL sodium phosphate buffer (pH 8.0), 100 mg animal feed fat and 0.25 U / g lipase mutant or wild type;

[0091] (2) The reaction mixture obtained in step (1) was incubated at 37° C. and 200 rpm for 24 hours, and the lipase hydrolysis was observed.

[0092] Figure 4 Determination of the hydrolysis of fats and oils in animal feed by wild-type and mutant lipases;

[0093] The results showed that after 24 hours, the water phase of the group with the lipase mutant added was more turbid than that of the group with the wild-type lipase added, and the degree of hydrolysis of oil was higher. This shows that compared with the wild-type lipase, the mutant I157V lipase has a more significant hydrolysis effect. The lipase mutant prepared by the present invention can effectively hydrolyze oil in animal feed, and has potential application value in the hydrolysis of oil in animal feed processing.

[0094] Note: The above embodiments are only used to illustrate the present invention and are not intended to limit the technical solutions described in the present invention; therefore, although this specification has described the present invention in detail with reference to the above embodiments, those skilled in the art should understand that the present invention can still be modified or replaced by equivalents.

[0095] It is obvious to those skilled in the art that various modifications and variations can be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. All technical solutions and improvements thereof that do not depart from the spirit and scope of the present invention should be included in the scope of the claims of the present invention.

[0096] Sequence Listing

[0097] SEQ ID NO.1

[0098] Ala Glu His Asn Pro Val Val Met Val His Gly Ile Gly Gly Ala Ser PheAsn Phe Ala Gly IleLys Ser Tyr Leu Val Ser Gln Gly Trp Ser Arg Asp Lys LeuTyr Ala Val Asp Phe Trp Asp Lys ThrGly Thr Asn Tyr Asn Asn Gly Pro Val LeuSer Arg Phe Val Gln Lys Val Leu Asp Glu Thr GlyAla Lys Lys Val Asp Ile ValAla His Ser Cys Gly Gly Ala Asn Thr Leu Tyr Tyr Ile Lys Asn LeuAsp Gly GlyAsn Lys Val Ala Asn Val Val Thr Leu Gly Gly Ala Asn Arg Leu Thr Thr GlyLysAla Leu Pro Gly Thr Asp Pro Asn Gln Lys Ile Leu Tyr Thr Ser Ile Tyr SerSer Val Asp Met IleVal Met Asn Tyr Leu Ser Arg Leu Asp Gly Ala Arg Asn ValGln Ile His Gly Val Gly His Ile GlyLeu Leu Tyr Ser Ser Gln Val Asn Ser LeuIle Lys Glu Gly Leu Asn Gly Gly Gly Gln Asn ThrAsn

[0099] SEQ ID NO.2

[0100] Phe Ala Gly Ile Lys Ser Tyr Leu Val Ser Gln Gly Trp Ser Arg Asp LysLeu Tyr Ala Val AspPhe Trp Asp Lys Thr Gly Thr Asn Tyr Asn Asn Gly Pro ValLeu Ser Arg Phe Val Gln Lys Val LeuAsp Glu Thr Gly Ala Lys Lys Val Asp IleVal Ala His Ser Cys Gly Gly Ala Asn Thr Leu Tyr TyrIle Lys Asn Leu Asp GlyGly Asn Lys Val Ala Asn Val Val Thr Leu Gly Gly Ala Asn Arg Leu ThrThr GlyLys Ala Leu Pro Gly Thr Asp Pro Asn Gln Lys Ile Leu Tyr Thr Ser Ile Tyr SerSer ValAsp Met Ile Val Met Asn Tyr Leu Ser Arg Leu Asp Gly Ala Arg Asn ValGln Ile His Gly Val GlyHis Val Gly Leu Leu Tyr Ser Ser Gln Val Asn Ser LeuIle Lys Glu Gly Leu Asn Gly Gly Gly GlnAsn Thr Asn

[0101] SEQ ID NO.3

[0102] gcagaacata atccggttgt aatggtacat ggtattggtg gtgcaagttt taattttgcaggtattaaaa gctatctggt tagtcagggt

[0103] tggagtcgtg ataaactgta tgcagttgat ttttgggata aaaccggtac gaattataataacggtccgg tactgagccg ttttgttcag

[0104] aaagttctgg atgaaaccgg tgcaaaaaaa gttgatattg ttgcacatag ctgtggtggtgcaaataccc tgtattatat taaaaatctg

[0105] gatggtggta ataaagttgc aaatgttgtt accctgggtg gtgcaaatcg tctgaccaccggtaaagcac tgccgggtac

[0106] cgatccgaat cagaaaattc tgtataccag catttatagc agcgttgata tgattgttatgaattatctg agccgtctgg atggtgcacg

[0107] taatgttcag attcatggtg ttggtcatgt tggtctgctg tatagcagcc aggttaatagcctgattaaa gaaggtctga atggtggtgg

[0108] tcagaatacc aat。

Claims

1. A Bacillus subtilis lipase mutant, characterized in that: The Bacillus subtilis lipase mutant is obtained by mutating the wild-type lipase with an amino acid sequence as shown in SEQ ID NO.1, and the mutation is that the 157th isoleucine is changed to valine.

2. A Bacillus subtilis lipase mutant according to claim 1, characterized in that: The amino acid sequence of the Bacillus subtilis lipase mutant is shown in SEQ ID NO.

2.

3. A gene encoding the Bacillus subtilis lipase mutant according to claim 1.

4. The gene according to claim 3, characterized in that The nucleotide sequence of the gene is shown in SEQ ID NO.3; or a nucleotide sequence that encodes the same protein as the coding gene SEQ ID NO.3, but is different from the nucleotide sequence shown in SEQ ID NO.3 or its complementary sequence due to the degeneracy of the genetic code.

5. A recombinant expression vector, characterized in that: Comprising the gene according to claim 4.

6. A genetically engineered bacterium, characterized in that: The preparation method of the recombinant genetically engineered bacteria is as follows: the gene described in claim 4 is cloned into the expression vector pTXB1, and the competent cells of Escherichia coli are transformed to obtain the recombinant genetically engineered bacteria.

7. The method for preparing the Bacillus subtilis lipase mutant according to claim 1, characterized in that: The following steps are involved: (1) Using the recombinant plasmid containing the Bacillus subtilis lipase gene linked to the vector pTXB1 as a template, primers were designed to perform site-directed mutagenesis PCR amplification to obtain mutant products; (2) Then add 1 μL of DnpⅠ digestion enzyme to 10 μL of mutant product, mix well, and incubate in a PCR instrument at 37°C for 60 min to obtain the digestion product; (3) Add 10 μL of digestion product to 100 μL of DH5α competent cells, cool in an ice bath, heat shock, and then cool again, add 500-700 μL of LB medium, culture at 37°C, 180 rpm for 1-2 h, retain 100-150 μL of supernatant to suspend the precipitate after centrifugation, and spread the bacterial solution on the plate, and culture in a constant temperature incubator at 37°C for 16 h; (4) Screening and verification of positive clones: single colonies were selected and placed in LB medium. After culturing at 37°C and 180 rpm for 5-6 h, PCR identification was performed. The screened positive clones were sent for sequencing, and the sequencing results were compared with the original sequences. (5) Based on the operation of step (4), find the recombinant plasmid with the correct mutation; transfer the mutant plasmid into BL21 (DE3) competent cells for expression; and then ferment and purify to obtain the Bacillus subtilis lipase mutant.

8. The method for preparing the Bacillus subtilis lipase mutant according to claim 7, characterized in that: The primers for site-directed mutagenesis are: F: TTCATGGTGTTGGTCATGTTGGTCTGCTGTATAG; R: TATACAGCAGACCAACATGACCAACACCATGAATC.

9. Use of the Bacillus subtilis lipase mutant as claimed in claim 1 in hydrolyzing fats and oils in animal feed.

10. A feed additive product, characterized in that: The invention comprises the Bacillus subtilis lipase mutant according to claim 1 or 2.

Citation Information

Cited By

  • Lipase mutant and application thereof

    CN121759433A